Valuation: Abivax

Market Cap 9.37B 10.95B 8.75B 8.03B 15.08B 1,048B 15.38B 104B 40.45B 525B 41.11B 40.22B 1,738B P/E 2026 *
-28.3x
P/E 2027 * -33.3x
Enterprise Value 8.27B 9.66B 7.72B 7.08B 13.31B 924B 13.57B 91.56B 35.69B 463B 36.28B 35.49B 1,534B EV / Sales 2026 *
110x
EV / Sales 2027 * 101x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.80%
1 week-1.66%
Current month-4.99%
1 month-14.04%
3 months-3.90%
6 months-8.35%
Current year-16.11%
1 week 99.55
Extreme 99.55
105.9
1 month 99.55
Extreme 99.55
117.8
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.87
Extreme 3.87
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Fiscal year

Chief Executive Officer

17,728 0.0222%
7/11/26 Fiscal year

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
+0.80%-1.66%+61.86%+493.42% 10.95B
-0.09%+3.87%+3.07%+24.37% 51.22B
-1.36%+4.82%+485.55%+614.84% 45.38B
-2.04%+3.69%+19.34%+91.23% 41.97B
+2.72%+6.02%+33.33%+19.66% 42.15B
0.00%-3.91%+18.49%+47.98% 31.95B
-1.85%+3.48% - - 16.73B
+0.72%+5.27%+31.55%+145.37% 17.1B
-0.80%+2.56%+6.24%+34.38% 14.76B
+0.50%+3.62%+82.64%+46.53% 13.91B
Average -0.14%+2.31%+82.45%+168.64% 28.61B
Weighted average by Cap. -0.18%+2.83%+101.93%+164.76%

Financials

2026 *2027 *
Net sales 74.92M 87.51M 69.9M 64.14M 121M 8.37B 123M 829M 323M 4.2B 329M 321M 13.89B 82.73M 96.63M 77.19M 70.83M 133M 9.25B 136M 916M 357M 4.63B 363M 355M 15.34B
Net income -265M -310M -247M -227M -427M -29.63B -435M -2.93B -1.14B -14.85B -1.16B -1.14B -49.16B -231M -269M -215M -198M -371M -25.79B -378M -2.55B -996M -12.92B -1.01B -990M -42.78B
Net Debt -1.1B -1.29B -1.03B -944M -1.77B -123B -1.81B -12.2B -4.76B -61.75B -4.84B -4.73B -204B -993M -1.16B -926M -850M -1.6B -111B -1.63B -10.99B -4.28B -55.59B -4.35B -4.26B -184B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-08-21 101.00 +0.80% 10,536
26-08-20 €100.20 -3.00% 101,763
26-08-19 €103.30 +0.39% 88,269
26-08-18 €102.90 -2.83% 61,836
26-08-17 €105.90 +3.12% 121,638
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
100.20EUR
Average target price
138.97EUR
Spread / Average Target
+38.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock